Beyer Russell P's Form 4 filing
SAB Biotherapeutics, Inc. (SABS) · filed Nov 16, 2021
- Accession no.
- 0001493152-21-028917
- Filed
- Nov 16, 2021
- Trade date
- Sep 28-Oct 26, 2021
- Filing delay
- 49 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $2.20K. It was filed 49 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Beyer Russell PCIK 0001889754 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 18, 2021 | Common Stock | AGrant or awardAcquired | +2,475 | $10.10 | +$24,997.5 | 2,475 | Direct | |
| Sep 28, 2021 | Common Stock | AGrant or awardAcquired | +149 | $10.08 | +$1,501.92 | 149 | Indirect | |
| Oct 25, 2021 | Common Stock | AGrant or awardAcquired | +129 | $7.78 | +$1,003.62 | 278 | Indirect | |
| Oct 26, 2021 | Common Stock | SSaleDisposed | −278 | $7.90 | −$2,196.2 | 0 | Indirect | |
| Sep 28, 2021 | Common Stock | AGrant or awardAcquired | +5 | $10.07 | +$50.35 | 5 | Indirect | |
| Sep 29, 2021 | Common Stock | AGrant or awardAcquired | +10 | $10.08 | +$100.8 | 15 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.